Oral omecamtiv mecarbil: Phase II started

Amgen began a double-blind, placebo-controlled, Japanese Phase II trial to evaluate 25, 37.5 and 50 mg oral omecamtiv mecarbil twice daily in about 80 patients with chronic stable heart failure and re...